Literature DB >> 903193

ADCC effector cells in a murine adenocarcinoma. I. Evidence for blood-borne bone-marrow-derived monocytes.

J S Haskill.   

Abstract

The origin and identity of effector cells for anti-body-dependent cell-mediated cytotoxicity and/or growth inhibition (ADCC) found in the murine mammary adenocarcinoma T1699 were investigated. Non-phagocytic, non-adherent ADCC effector cells were identified in bone marrow, peripheral blood and the host fraction of the tumor but not from lymphoid organs. These cells were shown to be distinct from the specific growth-inhibitory "armed monocytes" also identified in situ. The ADCC effector cells possess low levels of EA Fc receptors and appear to express a macrophage-associated antigen. Both the bone-marrow and the in situ effector cells became phagocytic after overnight incubation, providing further evidence for the monocyte-macrophage lineage of these cells. The results suggest that bone-marrow-derived blood-borne monocytes are the principal ADCC effector cells localizing in the mammary adenocarcinoma T1699. The parallels between tumor-induced immunity and cellular resistance to infectious agents involving hypersensitivity reactions and blood-borne monocytes are discussed.

Entities:  

Mesh:

Year:  1977        PMID: 903193     DOI: 10.1002/ijc.2910200316

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Human monocyte antibody-dependent cell-mediated cytotoxicity to tumor cells.

Authors:  G M Shaw; P C Levy; A F LoBuglio
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

2.  Separation of cell-dependent antibody (CDA) and inhibitory antibody by protein-A affinity chromatography and the effect of fractions on antibody-dependent cellular cytotoxicity (ADCC).

Authors:  N Sato; Y Yabuki; K Toh; Y Ishii; K Kikuchi
Journal:  Immunology       Date:  1979-03       Impact factor: 7.397

3.  Cells bearing Fc receptors in human malignant solid tumours.

Authors:  J L Svennevig; T R Andersson
Journal:  Br J Cancer       Date:  1982-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.